An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial

Wang, Thomas H, Bhatt, Deepak L, Fox, Keith A A, Steinhubl, Steven R, Brennan, Danielle M, Hacke, Werner, Mak, Koon-Hou, Pearson, Thomas A, Boden, William E, Steg, P Gabriel, Flather, Marcus D, Montalescot, Gilles, Topol, Eric J and , CHARISMA Investigators (2007) An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal, 28 (18). pp. 2200-7. ISSN 0195-668X

Full text not available from this repository. (Request a copy)

Abstract

To examine the unanticipated, excess mortality observed in patients randomized to clopidogrel and aspirin vs. aspirin alone in the prespecified 'asymptomatic' subgroup of CHARISMA, we investigated whether dual-antiplatelet therapy may be associated with adverse cardiovascular (CV) events in a primary prevention population.

Item Type: Article
Uncontrolled Keywords: aged,aspirin,atherosclerosis,cardiovascular diseases,disease-free survival,drug therapy, combination,epidemiologic methods,female,hemorrhage,humans,male,middle aged,myocardial infarction,platelet aggregation inhibitors,stroke,ticlopidine
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 06 Jan 2014 15:18
Last Modified: 21 Apr 2020 22:34
URI: https://ueaeprints.uea.ac.uk/id/eprint/46271
DOI: 10.1093/eurheartj/ehm274

Actions (login required)

View Item View Item